Similar articles

• Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.

  Conter V, Valsecchi MG, Buldini B, Parasole R, Locatelli F, Colombini A, Rizzari C, Putti MC, Barisone E, Lo Nigro L, Santoro N, Ziino O, Pession A, Testi AM, Micalizzi C, Casale F, Pierani P, Cesaro S, Cellini M, Silvestri D, Cazzaniga G, Biondi A, Basso G. Conter V, et al. Lancet Haematol. 2016 Feb;3(2):e80-6. doi: 10.1016/S2352-3026(15)00254-9. Epub 2016 Jan 26. Lancet Haematol. 2016. PMID: 26853647
• Immunoglobulin gene rearrangement in detection of minimal residual disease in acute lymphoblastic leukaemia.

  Nayyar A, Ahmed S. Nayyar A, et al. J Ayub Med Coll Abbottabad. 2013 Jan-Jun;25(1-2):159-61. J Ayub Med Coll Abbottabad. 2013. PMID: 25098084
• Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia.

  Eckert C, Biondi A, Seeger K, Cazzaniga G, Hartmann R, Beyermann B, Pogodda M, Proba J, Henze G. Eckert C, et al. Lancet. 2001 Oct 13;358(9289):1239-41. doi: 10.1016/S0140-6736(01)06355-3. Lancet. 2001. PMID: 11675066
• The detection of minimal residual disease in acute lymphoblastic leukaemia.

  Potter MN. Potter MN. Blood Rev. 1992 Jun;6(2):68-82. doi: 10.1016/0268-960x(92)90009-f. Blood Rev. 1992. PMID: 1633509 Review.
• Molecular measurement of minimal residual disease in Philadelphia-positive acute lymphoblastic leukaemia.

  Radich JP. Radich JP. Best Pract Res Clin Haematol. 2002 Mar;15(1):91-103. doi: 10.1053/beha.2002.0187. Best Pract Res Clin Haematol. 2002. PMID: 11987918 Review.